PASITHEA THERAPEUTICS CORP (KTTA) Stock News

NASDAQ:KTTA - Nasdaq - US70261F2020 - Common Stock - Currency: USD

0.7 +0.02 (+2.94%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

KTTA Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: Pasithea

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

2 months ago - By: Pasithea

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

2 months ago - By: Pasithea

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

3 months ago - By: Pasithea

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

3 months ago - By: Pasithea

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

3 months ago - By: Pasithea

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

3 months ago - By: Benzinga - Mentions: PTN HALO MYGN AGL ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

3 months ago - By: Yahoo Finance - Mentions: DHI CMG 2015 9988 ...

Pasithea Therapeutics 3.57M share Secondary priced at $1.40

3 months ago - By: Pasithea

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

3 months ago - By: Benzinga

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results

3 months ago - By: Pasithea

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

4 months ago - By: Pasithea

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

4 months ago - By: Pasithea

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

4 months ago - By: Pasithea

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

5 months ago - By: Pasithea

Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference